ArticleMethods in molecular biology (Clifton, N.J.)2026
Modeling Somitogenesis and Axial Development In Vitro with Axioloids.
Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Axioloids are three-dimensional (3D) structures derived from pluripotent stem cells (PSCs) that model key aspects of human somitogenesis and early axis development in vitro. These mesoderm-based aggregates recapitulate essential morphogenetic features of the segmentation process, including axial elongation, sequential formation of epithelial somites with proper rostrocaudal patterning, and oscillatory activity of the segmentation clock. They further reproduce the spatiotemporal organization characteristic of early axial development, such as opposing FGF/WNT and retinoic acid signaling gradients and anteroposterior HOX gene expression patterns similar to those observed in vivo. Together, these attributes highlight axioloids as a robust and versatile platform for studying human axial development and congenital disorders of the spine and axial skeleton. In this chapter, we provide a concise, step-by-step protocol for generating axioloids, along with key developmental readouts and troubleshooting strategies to address common problems and issues encountered. This protocol provides a reproducible framework for producing and characterizing axioloids as an in vitro model of human axial development and disease.
Indexed as
Identifiers
42020836What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.